¼¼°èÀÇ Ç÷ç¿À·¹¼¼ÀÎ Ç÷°üÁ¶¿µ ½ÃÀå
Fluorescein Angiography
»óǰÄÚµå : 1777338
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 373 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,186,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,559,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ Ç÷ç¿À·¹¼¼ÀÎ Ç÷°üÁ¶¿µ ½ÃÀåÀº 2030³â±îÁö 13¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 8¾ï 2,950¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â Ç÷ç¿À·¹¼¼ÀÎ Ç÷°üÁ¶¿µ ¼¼°è ½ÃÀåÀº 2024-2030³â°£ CAGR 7.7%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 13¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ±âÁ¸ Ç÷ç¿À·¹¼¼ÀÎ Ç÷°üÁ¶¿µÀº CAGR 8.8%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 9¾ï 2,280¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. °øÃÊÁ¡ ÁÖ»çÇü ·¹ÀÌÀú °Ë¾È°æ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£¿¡ CAGR 5.3%·Î ÃßÁ¤µÇ°í ÀÖ½À´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 2¾ï 2,600¸¸ ´Þ·¯, Áß±¹Àº CAGR12.2%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Ç÷ç¿À·¹¼¼ÀÎ Ç÷°üÁ¶¿µ½ÃÀåÀº 2024³â¿¡ 2¾ï 2,600¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 12.2%·Î ¼ºÀåÀ» Áö¼ÓÇÏ¿© 2030³â±îÁö 2¾ï 7,780¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 3.8%¿Í 7.4%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 5.1%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ Ç÷ç¿À·¹¼¼ÀÎ Ç÷°üÁ¶¿µ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¾È°ú¿¡¼­ Ç÷ç¿À·¹¼¼ÀÎ Ç÷°üÁ¶¿µ¼úÀÇ Á߿伺ÀÌ Ä¿Áö´Â ÀÌÀ¯´Â?

Ç÷ç¿À·¹¼¼ÀÎ Ç÷°üÁ¶¿µ¼ú(FA)Àº ¸Á¸·°ú ¸Æ¶ô¸·ÀÇ Ç÷·ù¸¦ Æò°¡ÇÏ¿© ´ç´¢¸Á¸·º´Áõ, ³ëÀμº Ȳ¹Ýº¯¼º(AMD), ¸Á¸·Á¤¸ÆÆó¼âÁõ°ú °°Àº ¾ÈÁúȯÀÇ Á¶±â ¹ß°ß ¹× °ü¸®¿¡ µµ¿òÀÌ µÇ´Â Áß¿äÇÑ ¿µ»óÁø´Ü ±â¼úÀÔ´Ï´Ù. ´ç´¢º´ À¯º´·ü Áõ°¡¿Í ¼¼°è Àα¸ÀÇ °í·ÉÈ­´Â ÷´Ü ¸Á¸· ¿µ»ó ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿ø°Ý ¾È°ú ÀÇ·á¿Í AI¸¦ Ȱ¿ëÇÑ ¿µ»ó ºÐ¼®ÀÇ °³¼±À¸·Î FA ½Ã¼úÀÇ Á¢±Ù¼º°ú Á¤È®¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ½Ã°¢ °ü·Ã ÁúȯÀÇ ºÎ´ãÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü´Â Á¤È®ÇÑ Áø´Ü ¹× Ä¡·á °èȹÀ» À§ÇØ Ç÷ç¿À·¹¼¼ÀÎ Ç÷°ü Á¶¿µ¼ú¿¡ ´ëÇÑ ÀÇÁ¸µµ°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.

Ç÷ç¿À·¹¼¼ÀÎ Ç÷°üÁ¶¿µ¼úÀ» Çâ»ó½ÃŰ´Â ±â¼ú ¹ßÀüÀº ¾î¶² °ÍÀÌ Àִ°¡?

°í¼Ó µðÁöÅÐ ¿µ»ó, AI¸¦ Ȱ¿ëÇÑ Áø´Ü µµ±¸, Ãʱ¤½Ã¾ß Ç÷°üÁ¶¿µ¼úÀÇ ¹ßÀüÀÌ FA ±â¼úÀ» º¯È­½Ã۰í ÀÖ½À´Ï´Ù. AI°¡ žÀçµÈ ¿µ»ó ºÐ¼® ¼ÒÇÁÆ®¿þ¾î´Â ºñÁ¤»óÀûÀÎ Ç÷°ü ÆÐÅϰú ´©ÃâÀ» ÀÚµ¿À¸·Î ½Äº°ÇÏ¿© Áúº´ÀÇ Á¶±â ¹ß°ßÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ºû°£¼·´ÜÃþÃÔ¿µ(OCTA)°ú °°Àº ºñħ½ÀÀûÀ̰í Á¶¿µÁ¦¸¦ »ç¿ëÇÏÁö ¾Ê´Â Ç÷°üÁ¶¿µ ±â¼úÀÇ °³¹ßÀº Áø´ÜÀÇ Á¤È®¼ºÀ» À¯ÁöÇϸ鼭 ȯÀÚÀÇ ºÒÆíÇÔÀ» ÁÙ¿©ÁÖ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Ãʺб¤ ¿µ»óÀÇ ±â¼ú Çõ½ÅÀ¸·Î ¸Á¸· ¹Ì¼¼¼øÈ¯À» º¸´Ù ¼¼¹ÐÇÏ°Ô ½Ã°¢È­ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. Ŭ¶ó¿ìµå ±â¹Ý ¾È°ú ¿µ»ó Ç÷§ÆûÀÇ ÅëÇÕÀ¸·Î Àü¹®ÀÇ °£ÀÇ Çù·ÂÀÌ °³¼±µÇ¾î ¿ø°Ý Áø´Ü ¹× 2Â÷ Áø·á°¡ ¿ëÀÌÇØÁ³½À´Ï´Ù.

±ÔÁ¦¿Í ½ÃÀå µ¿ÇâÀº Ç÷ç¿À·¹¼¼ÀÎ Ç÷°üÁ¶¿µ¼ú¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¡°í Àִ°¡?

FDA, EMA, WHO µî ±ÔÁ¦±â°üÀº FA °Ë»ç¿¡ »ç¿ëµÇ´Â Á¶¿µÁ¦¿¡ ¾ö°ÝÇÑ °¡À̵å¶óÀÎÀ» Àû¿ëÇÏ¿© ȯÀÚÀÇ ¾ÈÀü°ú ¿µ»ó ǰÁúÀ» º¸ÀåÇϰí ÀÖ½À´Ï´Ù. ºñħ½ÀÀû Áø´Ü ¹æ¹ýÀ¸·ÎÀÇ ÀüȯÀº ºÎÀÛ¿ëÀÌ ÀûÀº ´ëü Ç÷°üÁ¶¿µ¼ú¿¡ ´ëÇÑ ¿¬±¸¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, AI Áö¿ø ¾È°úÀÇ È®´ë°¡ ½ÃÀå Æ®·»µå¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖÀ¸¸ç, º¸´Ù ½Å¼ÓÇϰí Á¤È®ÇÑ Áø´Ü ¿öÅ©Ç÷ο츦 °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÈÞ´ë¿ë ¹× °¡Á¤¿ë ¸Á¸· ¿µ»ó ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¼ÒÇü FA ÀåºñÀÇ °³¹ßÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ¾È°ú ¿µ»ó ±â¼úÀÇ ¹ßÀü¿¡ µû¶ó Ç÷ç¿À·¹¼¼ÀÎ Ç÷°üÁ¶¿µ¼úÀº ȯÀÚ Ä£È­ÀûÀ̰í Áø´Ü È¿À²ÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù.

Ç÷ç¿À·¹¼¼ÀÎ Ç÷°üÁ¶¿µ¼ú ½ÃÀåÀÇ ÇâÈÄ ¼ºÀå µ¿·ÂÀº?

FAÀÇ ¹Ì·¡´Â AI¸¦ Ȱ¿ëÇÑ ¿¹Ãø Áø´Ü, Â÷¼¼´ë ¿µ»ó Á¶¿µÁ¦, ¾È°ú ¿ø°ÝÀÇ·áÀÇ ÅëÇÕÀ¸·Î Çü¼ºµÇ°í ÀÖ½À´Ï´Ù. ¸ÂÃãÇü ÀÇ·á¿Í Ç¥ÀûÄ¡·áÀÇ ºÎ»óÀº º¸´Ù Á¤¹ÐÇÑ ¸Á¸·¿µ»óÁø´Ü ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÒ °ÍÀÔ´Ï´Ù. AI Áö¿ø ÀÇ»ç°áÁ¤ µµ±¸ÀÇ È°¿ëÀÌ ´Ã¾î³ª¸é Áø´Ü Á¤È®µµ¿Í ¿öÅ©Ç÷οì È¿À²¼ºÀÌ ´õ¿í Çâ»óµÉ °ÍÀÔ´Ï´Ù. ¶ÇÇÑ, ºñħ½ÀÀûÀÌ°í ¶óº§ÀÌ ÇÊ¿ä ¾ø´Â ¿µ»ó ±â¼úÀÇ °³¹ß·Î »ö¼Ò ±â¹Ý Ç÷°ü Á¶¿µ¼ú¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ³·Ãç ȯÀÚÀÇ À§ÇèÀ» ÃÖ¼ÒÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ½Ã·ÂÄ¡·á°¡ °è¼Ó ¹ßÀüÇÏ´Â °¡¿îµ¥ FA´Â ¾È°ú Áø´ÜÀÇ ÇÙ½ÉÀ¸·Î Áúº´ÀÇ Á¶±â ¹ß°ß°ú ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÏ´Â µ¥ µµ¿òÀ» ÁÝ´Ï´Ù.

ºÎ¹®

À¯Çü(±âÁ¸ Ç÷ç¿À·¹¼¼ÀÎ Ç÷°üÁ¶¿µ, °øÃÊÁ¡ ·¹ÀÌÀú °Ë¾È°æ), ¿ëµµ(³ëÀÎȲ¹Ýº¯¼º, ´ç´¢º´¼º ¸Á¸·Áõ, ¸Á¸· Á¤¸Æ Æó¼âÁõ, Æ÷µµ¸·¿° ¹× ¸Á¸· Ç÷°ü¿°, ¸Æ¶ô¸· Á¾¾ç, ±âŸ), ÃÖÁ¾ ¿ëµµ(º´¿ø ¹× Ŭ¸®´Ð, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC), ±âŸ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

´ç»ç´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Fluorescein Angiography Market to Reach US$1.3 Billion by 2030

The global market for Fluorescein Angiography estimated at US$829.5 Million in the year 2024, is expected to reach US$1.3 Billion by 2030, growing at a CAGR of 7.7% over the analysis period 2024-2030. Traditional Fluorescein Angiography, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$922.8 Million by the end of the analysis period. Growth in the Confocal Scanning Laser Ophthalmoscopy segment is estimated at 5.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$226.0 Million While China is Forecast to Grow at 12.2% CAGR

The Fluorescein Angiography market in the U.S. is estimated at US$226.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$277.8 Million by the year 2030 trailing a CAGR of 12.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.8% and 7.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.1% CAGR.

Global Fluorescein Angiography Market - Key Trends & Drivers Summarized

Why Is Fluorescein Angiography Gaining Importance in Ophthalmology?

Fluorescein angiography (FA) is a vital diagnostic imaging technique used to assess blood flow in the retina and choroid, aiding in the early detection and management of eye disorders such as diabetic retinopathy, age-related macular degeneration (AMD), and retinal vein occlusions. The rising prevalence of diabetes and an aging global population are fueling demand for advanced retinal imaging solutions. Additionally, improvements in teleophthalmology and AI-powered image analysis are enhancing the accessibility and accuracy of FA procedures. As the burden of vision-related diseases grows, healthcare providers are increasingly relying on fluorescein angiography for accurate diagnosis and treatment planning.

What Technological Advancements Are Improving Fluorescein Angiography?

Advancements in high-speed digital imaging, AI-driven diagnostic tools, and ultra-widefield angiography are transforming FA technology. AI-powered image analysis software is improving early disease detection by automatically identifying abnormal vascular patterns and leakages. The development of non-invasive and contrast-free angiography techniques, such as optical coherence tomography angiography (OCTA), is reducing patient discomfort while maintaining diagnostic accuracy. Additionally, innovations in hyperspectral imaging are enabling more detailed visualization of retinal microcirculation. The integration of cloud-based ophthalmic imaging platforms is also improving collaboration between specialists, facilitating remote diagnosis and second-opinion consultations.

How Are Regulations and Market Trends Influencing Fluorescein Angiography?

Regulatory agencies such as the FDA, EMA, and WHO enforce strict guidelines for contrast agents used in FA procedures, ensuring patient safety and imaging quality. The shift toward non-invasive diagnostic methods is driving research into alternative angiography techniques with fewer side effects. Additionally, the expansion of AI-assisted ophthalmology is influencing market trends, allowing for faster and more precise diagnostic workflows. The rising demand for portable and home-based retinal imaging solutions is also encouraging the development of compact FA devices. As ophthalmic imaging technology evolves, fluorescein angiography is becoming more patient-friendly and diagnostically efficient.

What’s Driving the Future Growth of the Fluorescein Angiography Market?

The future of FA is being shaped by AI-powered predictive diagnostics, next-generation imaging contrast agents, and the integration of telemedicine in ophthalmology. The rise of personalized medicine and targeted therapies will drive demand for more precise retinal imaging techniques. The increasing use of AI-assisted decision-making tools will further improve diagnostic accuracy and workflow efficiency. Additionally, the development of non-invasive, label-free imaging technologies will reduce reliance on dye-based angiography, minimizing patient risks. As vision care continues to advance, FA will remain a cornerstone of ophthalmic diagnostics, supporting early disease detection and improved patient outcomes.

SCOPE OF STUDY:

The report analyzes the Fluorescein Angiography market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Traditional Fluorescein Angiography, Confocal Scanning Laser Ophthalmoscopy); Application (Age-related Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion, Uveitis & Retinal Vasculitis, Choroidal Tumors, Others); End-Use (Hospitals & Clinics, Ambulatory Surgery Centers, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â